Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: An algorithm for the pre-emptive use of plerixafor

Research output: Contribution to journalArticle

Abstract

Plerixafor "on demand" after chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) is efficient in peripheral stem cell mobilization, but the timing of administration and criteria for patient selection are under investigation. To devise an algorithm for the "on demand" use of plerixafor at the first mobilization attempt, we analyzed the kinetics of hematopoietic recovery and peripheral blood CD34+ cells in 107 patients treated with high-dose cyclophosphamide plus G-CSF. Fifty-one patients with myeloma were treated with cyclophosphamide 3-4 g/m2 on day 0 followed by G-CSF 10 ug/kg from day + 6, and 56 patients with lymphoma received cyclophosphamide 6-7 g/m2 followed by G-CSF 5 μg/kg from day +1. Peripheral blood CD34+ cell monitoring was started on day + 8 in patients with myeloma and day + 10 in patients with lymphoma. The outcome of interest was a collection of ≤ 2 × 106 CD34+/kg. By a multivariate logistic regression model, CD34+ cell count 1000/μL) or leukocyte count

Original languageEnglish
Pages (from-to)331-336
Number of pages6
JournalLeukemia and Lymphoma
Volume55
Issue number2
DOIs
Publication statusPublished - 2014

Keywords

  • Lymphoma
  • Myeloma
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: An algorithm for the pre-emptive use of plerixafor'. Together they form a unique fingerprint.

  • Cite this